Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genetic Testing | 36 | 2025 | 50 | 3.820 |
Why?
|
| Genetic Predisposition to Disease | 32 | 2025 | 63 | 3.530 |
Why?
|
| Genetic Variation | 26 | 2026 | 40 | 3.480 |
Why?
|
| Breast Neoplasms | 19 | 2025 | 170 | 2.580 |
Why?
|
| Germ-Line Mutation | 24 | 2025 | 28 | 2.370 |
Why?
|
| Tumor Suppressor Protein p53 | 14 | 2025 | 29 | 1.840 |
Why?
|
| BRCA1 Protein | 11 | 2025 | 13 | 1.360 |
Why?
|
| BRCA2 Protein | 10 | 2026 | 12 | 1.270 |
Why?
|
| Humans | 60 | 2026 | 6794 | 1.160 |
Why?
|
| Neoplasms | 9 | 2025 | 92 | 1.150 |
Why?
|
| Li-Fraumeni Syndrome | 7 | 2025 | 7 | 1.140 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 8 | 2025 | 8 | 0.970 |
Why?
|
| Mutation, Missense | 10 | 2025 | 17 | 0.920 |
Why?
|
| Sequence Analysis, DNA | 6 | 2020 | 18 | 0.900 |
Why?
|
| Genome, Human | 8 | 2024 | 8 | 0.890 |
Why?
|
| Adenomatous Polyposis Coli | 4 | 2024 | 4 | 0.770 |
Why?
|
| Genetic Association Studies | 6 | 2021 | 8 | 0.700 |
Why?
|
| Ovarian Neoplasms | 6 | 2024 | 35 | 0.700 |
Why?
|
| Female | 28 | 2026 | 4060 | 0.670 |
Why?
|
| Databases, Genetic | 7 | 2025 | 9 | 0.570 |
Why?
|
| Biomarkers, Tumor | 5 | 2021 | 51 | 0.550 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2024 | 6 | 0.540 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2025 | 18 | 0.490 |
Why?
|
| Checkpoint Kinase 2 | 5 | 2025 | 5 | 0.460 |
Why?
|
| Phenotype | 10 | 2025 | 91 | 0.450 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 4 | 2025 | 7 | 0.450 |
Why?
|
| Adenomatous Polyposis Coli Protein | 2 | 2024 | 2 | 0.380 |
Why?
|
| DNA-Binding Proteins | 3 | 2023 | 38 | 0.370 |
Why?
|
| High-Throughput Nucleotide Sequencing | 8 | 2019 | 23 | 0.370 |
Why?
|
| Neoplastic Syndromes, Hereditary | 3 | 2025 | 4 | 0.370 |
Why?
|
| Adult | 13 | 2025 | 2113 | 0.370 |
Why?
|
| Mutation | 8 | 2022 | 97 | 0.370 |
Why?
|
| Computational Biology | 6 | 2025 | 13 | 0.370 |
Why?
|
| Middle Aged | 12 | 2025 | 2108 | 0.320 |
Why?
|
| Genes, p53 | 2 | 2021 | 4 | 0.310 |
Why?
|
| Penetrance | 3 | 2025 | 4 | 0.310 |
Why?
|
| Case-Control Studies | 7 | 2025 | 108 | 0.310 |
Why?
|
| Alleles | 7 | 2025 | 22 | 0.310 |
Why?
|
| RNA Splice Sites | 4 | 2022 | 4 | 0.300 |
Why?
|
| Genomics | 6 | 2024 | 13 | 0.280 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2025 | 6 | 0.280 |
Why?
|
| Bayes Theorem | 3 | 2025 | 25 | 0.250 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 3 | 2021 | 5 | 0.250 |
Why?
|
| Computer Simulation | 3 | 2020 | 26 | 0.240 |
Why?
|
| Fanconi Anemia | 1 | 2025 | 1 | 0.240 |
Why?
|
| Fumarate Hydratase | 1 | 2025 | 1 | 0.230 |
Why?
|
| Leiomyomatosis | 1 | 2025 | 1 | 0.230 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2025 | 10 | 0.230 |
Why?
|
| Kidney Neoplasms | 1 | 2025 | 12 | 0.230 |
Why?
|
| Genes, BRCA2 | 2 | 2022 | 4 | 0.230 |
Why?
|
| Germ Cells | 5 | 2024 | 6 | 0.230 |
Why?
|
| Alternative Splicing | 3 | 2022 | 3 | 0.230 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2025 | 2 | 0.220 |
Why?
|
| Aged | 7 | 2025 | 1539 | 0.210 |
Why?
|
| RNA | 2 | 2022 | 25 | 0.200 |
Why?
|
| DNA Mismatch Repair | 2 | 2021 | 5 | 0.200 |
Why?
|
| Stomach Neoplasms | 1 | 2022 | 11 | 0.190 |
Why?
|
| United States | 6 | 2023 | 1019 | 0.180 |
Why?
|
| DNA Glycosylases | 1 | 2022 | 1 | 0.180 |
Why?
|
| Cohort Studies | 5 | 2021 | 285 | 0.180 |
Why?
|
| Succinate Dehydrogenase | 1 | 2021 | 1 | 0.180 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2021 | 2 | 0.180 |
Why?
|
| Carcinoma, Lobular | 1 | 2021 | 1 | 0.180 |
Why?
|
| Societies, Medical | 2 | 2018 | 67 | 0.170 |
Why?
|
| Recombinational DNA Repair | 1 | 2021 | 1 | 0.170 |
Why?
|
| Endometrial Neoplasms | 1 | 2021 | 25 | 0.170 |
Why?
|
| Genes, APC | 1 | 2020 | 1 | 0.170 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 3 | 0.160 |
Why?
|
| Laboratories | 2 | 2017 | 3 | 0.160 |
Why?
|
| Prognosis | 4 | 2021 | 220 | 0.160 |
Why?
|
| Guidelines as Topic | 2 | 2020 | 19 | 0.160 |
Why?
|
| Gene Duplication | 2 | 2018 | 2 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 84 | 0.150 |
Why?
|
| Tandem Repeat Sequences | 1 | 2018 | 1 | 0.140 |
Why?
|
| Direct-To-Consumer Screening and Testing | 1 | 2018 | 2 | 0.140 |
Why?
|
| Publications | 1 | 2018 | 5 | 0.140 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2018 | 10 | 0.140 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2017 | 6 | 0.130 |
Why?
|
| Nuclear Proteins | 1 | 2017 | 17 | 0.130 |
Why?
|
| Clinical Laboratory Information Systems | 1 | 2017 | 1 | 0.130 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2017 | 7 | 0.130 |
Why?
|
| RNA Splicing | 3 | 2023 | 6 | 0.130 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2015 | 2 | 0.120 |
Why?
|
| MutL Protein Homolog 1 | 3 | 2021 | 4 | 0.120 |
Why?
|
| Intestinal Polyposis | 1 | 2015 | 1 | 0.120 |
Why?
|
| Pseudogenes | 1 | 2015 | 2 | 0.120 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 2 | 0.120 |
Why?
|
| Smad4 Protein | 1 | 2015 | 3 | 0.120 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 1 | 2015 | 2 | 0.120 |
Why?
|
| Gene Deletion | 1 | 2015 | 17 | 0.110 |
Why?
|
| Male | 5 | 2025 | 3671 | 0.110 |
Why?
|
| Exons | 3 | 2020 | 8 | 0.110 |
Why?
|
| Heterozygote | 2 | 2025 | 9 | 0.100 |
Why?
|
| Young Adult | 3 | 2021 | 567 | 0.100 |
Why?
|
| Software | 3 | 2018 | 18 | 0.100 |
Why?
|
| Risk Factors | 3 | 2025 | 767 | 0.100 |
Why?
|
| Algorithms | 2 | 2024 | 83 | 0.090 |
Why?
|
| DNA | 2 | 2024 | 39 | 0.090 |
Why?
|
| Gene Frequency | 2 | 2023 | 12 | 0.090 |
Why?
|
| Medical History Taking | 2 | 2021 | 8 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 268 | 0.080 |
Why?
|
| Genotype | 2 | 2020 | 28 | 0.080 |
Why?
|
| Age of Onset | 2 | 2021 | 16 | 0.080 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 497 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2020 | 82 | 0.070 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 2 | 2019 | 2 | 0.070 |
Why?
|
| MutS Homolog 2 Protein | 2 | 2019 | 2 | 0.070 |
Why?
|
| Adolescent | 2 | 2021 | 869 | 0.070 |
Why?
|
| Sequence Alignment | 2 | 2020 | 6 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2026 | 13 | 0.060 |
Why?
|
| Hereditary Breast and Ovarian Cancer Syndrome | 1 | 2025 | 1 | 0.060 |
Why?
|
| DNA Mutational Analysis | 2 | 2016 | 15 | 0.060 |
Why?
|
| Genes, Neoplasm | 1 | 2024 | 1 | 0.050 |
Why?
|
| Exome | 1 | 2023 | 2 | 0.050 |
Why?
|
| North America | 1 | 2023 | 7 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2023 | 17 | 0.050 |
Why?
|
| Mice | 2 | 2022 | 746 | 0.050 |
Why?
|
| Cadherins | 1 | 2022 | 4 | 0.050 |
Why?
|
| Antigens, CD | 1 | 2022 | 21 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2022 | 190 | 0.050 |
Why?
|
| Virulence | 1 | 2021 | 5 | 0.050 |
Why?
|
| Datasets as Topic | 1 | 2021 | 5 | 0.050 |
Why?
|
| Chromosome Mapping | 1 | 2001 | 10 | 0.040 |
Why?
|
| Bile Acids and Salts | 1 | 2001 | 12 | 0.040 |
Why?
|
| Data Collection | 1 | 2021 | 38 | 0.040 |
Why?
|
| Hypercholesterolemia | 1 | 2001 | 13 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 127 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2021 | 9 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2020 | 2 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2020 | 13 | 0.040 |
Why?
|
| Animals | 2 | 2022 | 1875 | 0.040 |
Why?
|
| Databases, Protein | 1 | 2020 | 1 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2020 | 8 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2020 | 38 | 0.040 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 7 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2020 | 12 | 0.040 |
Why?
|
| Phylogeny | 1 | 2020 | 20 | 0.040 |
Why?
|
| Receptor, ErbB-2 | 1 | 2020 | 16 | 0.040 |
Why?
|
| Survival Rate | 1 | 2020 | 111 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 18 | 0.040 |
Why?
|
| Disease Management | 1 | 2020 | 33 | 0.040 |
Why?
|
| Genes, BRCA1 | 1 | 2019 | 2 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2019 | 2 | 0.040 |
Why?
|
| Decision Making | 1 | 2019 | 25 | 0.040 |
Why?
|
| Nonsense Mediated mRNA Decay | 1 | 2019 | 1 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 44 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2018 | 15 | 0.040 |
Why?
|
| DNA Breaks | 1 | 2018 | 2 | 0.040 |
Why?
|
| Genome | 1 | 2018 | 7 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 8 | 0.040 |
Why?
|
| Pedigree | 1 | 2017 | 7 | 0.030 |
Why?
|
| MRE11 Homologue Protein | 1 | 2017 | 1 | 0.030 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 2017 | 1 | 0.030 |
Why?
|
| Neurofibromin 1 | 1 | 2017 | 1 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2017 | 1 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2017 | 1 | 0.030 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2017 | 1 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2017 | 2 | 0.030 |
Why?
|
| RNA Helicases | 1 | 2017 | 3 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2017 | 22 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2019 | 500 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2017 | 16 | 0.030 |
Why?
|
| Consensus | 1 | 2017 | 39 | 0.030 |
Why?
|
| Registries | 1 | 2017 | 63 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2017 | 331 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2015 | 13 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 88 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 79 | 0.030 |
Why?
|
| Cholesterol 7-alpha-Hydroxylase | 1 | 2001 | 1 | 0.010 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2001 | 1 | 0.010 |
Why?
|
| Cholestanetriol 26-Monooxygenase | 1 | 2001 | 1 | 0.010 |
Why?
|
| Steroid Hydroxylases | 1 | 2001 | 3 | 0.010 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2001 | 3 | 0.010 |
Why?
|
| Cholesterol | 1 | 2001 | 37 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2001 | 258 | 0.010 |
Why?
|